In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bridging the Hot Economics of Monoclonals and Genomics

Executive Summary

Abgenix's recent deals with Human Genome Sciences and CuraGen bridge two of the hottest biotechnology markets--monoclonal antibodies and genomics. The deals are structured slightly differently, but both accomplish the same thing: the use of each other's technological asset to create proprietary programs.

You may also be interested in...



The State of Investing in Antibody Technology

Since December 2001, only two privately held antibody firms have raised more than $15 million in a round of financing. Moreover, the older public companies founded on the promise of disruptive antibody development technologies, principally Abgenix and Medarex with fully human antibodies, and Human Genome Sciences with its antibody-driven genomics discovery science, have yet to validate those platforms through successful clinical product development. Even antibody humanization specialist Protein Design Labs, which has marketed antibody products from which it's getting royalties, is still selling for not much more than its cash value. Yet despite a fall-off in investments in this core area of biotech drug development, VCs still say antibodies will provide a range of successful new therapies.

Takeda Culls Shunned Ex-Shire Asset After EC Lifts Antimonopoly Concerns

Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.

J&J’s Baby Powder Announcement Renews NGO Calls For Industry, FDA To End Use Of Talc In Cosmetics

The Environmental Working Group and US PIRG suggest that beauty and personal-care firms should avoid using talc in loose powders, if not all cosmetic products, and that the US FDA should consider banning the ingredient due to the potential for asbestos contamination, among other concerns.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel